Hopefully NP has learned his lesson. No revenue news after giving a hard timeline is a rookie mistake. But it doesn’t mean he was lying. He may have been assured his timeline was a done deal, but he is dealing with governments. Nothing is assured until the ink is dry.
On a side note, the Zoom Call video of Dr. Nichols, the Deputy of Congress and the head of the PI FDA was demonstrative. The FDA head made a statement to the effect of saying “let’s not forget who pays our bills” when pushed about approving therapeutics and specifically Leronlimab. His comment portended push back not from BP specifically, but rather from large US institutional banks who have very large BP positions in their portfolios.
These US banks have tremendous influence worldwide as about 80% of all business in the World is done using the Dollar. This is due to the fact that we are the World’s reserve currency (for now) and specifically are not only more trusted as a currency (for now) but also because oil is sold in dollars, And all countries need oil to run their economies.
My point is don’t underestimate the ability of large US banks and BP to thwart any threat to their monopoly investments. The flip side of this concern is that many countries in the world that are not friendly to the US - and the PI has a storied history with America in that regard - resent US financial power and pressure. We often manipulate their currencies to remind foreign countries of that reality (recent ex. - Turkish Lira). But poorer countries also have Socialist medical systems, not medical systems based on financial profit. So they have a huge incentive to save money with their treatment costs - a big plus for Leronlimab as it reduces hospital stays and potential expensive patient ICU admissions.
Lastly, to a degree NP is likely better received in these countries as a CEO since he was originally not from the US. He as born a foreigner like they are and grew up under a socialized medical system. Overall he is selling a product that has tremendous logistical, medical and cost advantages for use across a spectrum of treatment. We’ll see how this plays out. The overwhelming nature of Covid against poorer countries healthcare capabilities increases the likelihood of Leronlimab being approved in some diplomatic fashion in both language and administration. We will get good news from the PI, imo, but the timeline could be 4 times what NP recklessly stated. Hang in there longs. Stay calm and remain resolute. Our day is coming..
.
News 
Market Data 
Discover 
